Can the interplay between androgen signaling and PSMA expression be leveraged for theranostic applications?

Despite numerous approved therapies for metastatic prostate cancer (PCa) that offer advantages in progression free survival, actual cure rates remain dismal (1). Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is nearly universally expressed in PCa (2) and has emerged as one of the most promising targets for novel therapies that are being developed to address PCa (3). Of note, PSMA expression levels have a relationship with androgen signaling that may have important clinical implications for treatment with PSMA-targeted theranostic agents.